Decera Clinical Education Oncology Podcast

00:28:40

Experts Discuss Sequencing of Therapies for...

Decera Clinical Education Oncology Podcast ·

2026/09/30

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for ResearchPartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family

en

00:18:43

ASCO 2026 Updates in Metastatic Breast Cancer

Decera Clinical Education Oncology Podcast ·

2026/09/22

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomesEmerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus

en

00:35:21

Evolving Role of B7-H3–Directed ADCs in the...

Decera Clinical Education Oncology Podcast ·

2026/09/10

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for

en

00:29:16

Targeting CDH6 in Platinum-Resistant Ovarian Cancer:...

Decera Clinical Education Oncology Podcast ·

2026/09/04

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety

en

00:09:10

ASCO 2026 Updates in Early Hormone Receptor–Positive...

Decera Clinical Education Oncology Podcast ·

2026/09/04

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when

en

00:22:30

CELMoDs on the Horizon: A New Chapter in Lymphoma Care

Decera Clinical Education Oncology Podcast ·

2026/08/24

Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients

en

00:13:51

Experts Discuss Health Disparities and Equitable Care...

Decera Clinical Education Oncology Podcast ·

2026/08/20

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including:Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolment Presenters:Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma

en

00:26:03

Experts Discuss CELMoD Agents for Multiple Myeloma

Decera Clinical Education Oncology Podcast ·

2026/08/20

In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settings Presenters:Meletios-Athanasios (Thanos) C. Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of

en

00:32:42

Optimizing Oral Targeted Therapies for HR+/HER2-...

Decera Clinical Education Oncology Podcast ·

2026/08/14

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy.Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6

en

00:36:17

TGCT Today: Understanding Diagnosis, Treatment, and...

Decera Clinical Education Oncology Podcast ·

2026/08/13

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered

en

00:28:57

Optimizing Anti-CD38–Based Treatment for Smoldering...

Decera Clinical Education Oncology Podcast ·

2026/08/12

In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including:Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant

en

00:38:55

New and Emerging Targeted Therapies for Patients With...

Decera Clinical Education Oncology Podcast ·

2026/08/07

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including:Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice Key Ongoing Trials of new and novel agents in DLBCL Key Presentations/Results at EHA 2026 in DLBCL Presenters: Gilles

en

00:25:04

Changing the Paradigm in HER2-Positive Early Breast...

Decera Clinical Education Oncology Podcast ·

2026/08/07

New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. Presenters: Sara A. Hurvitz, MD, FACP Professor of Medicine Smith Family Endowed Chair in Women’s Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center

en

00:17:59

Recent Advances, Future Directions, and Ideas on...

Decera Clinical Education Oncology Podcast ·

2026/08/03

Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice.Presenters:Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta,

en

00:48:21

To Treat or Not to Treat: Assessing Risk and...

Decera Clinical Education Oncology Podcast ·

2026/07/29

In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including:Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient

en

00:22:12

Unmet Needs, Recent Advances, and Expert Insights on...

Decera Clinical Education Oncology Podcast ·

2026/07/28

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover:The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the

en

00:30:58

Optimizing Bispecific Antibody Safety and Care...

Decera Clinical Education Oncology Podcast ·

2026/07/23

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including:The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone,

en

00:28:50

Targeting the Future of Pancreatic Cancer Care: RAS,...

Decera Clinical Education Oncology Podcast ·

2026/07/22

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive care Get access to all of our new podcasts by

en

00:26:54

Beyond BCMA: How GPRC5D-Targeted Therapy Fits into...

Decera Clinical Education Oncology Podcast ·

2026/07/14

Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection

en

00:28:33

What Oncology Pharmacists Need to Know About...

Decera Clinical Education Oncology Podcast ·

2026/07/13

In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges

en

All Episodes

Similar Podcasts

Edutainment Learning

Ralph Krauss

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Education Futures

Svenia Busson & Laurent Jolie

Out In The Hall

NHSA